The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Kyowa Kirin; MSD; Novartis; Sanofi; Stemline Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Kyowa Kirin; MSD; Novartis; Sanofi; Stemline Therapeutics
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Jessica Cecile Hassel
Honoraria - Amgen; BMS GmbH & Co. KG; Bristol Myers Squibb Foundation; GlaxoSmithKline; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); GlaxoSmithKline; Immunocore (Inst); MSD; Novartis (Inst); Onkowissen; Philogen (Inst); Pierre Fabre; Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); Idera (Inst); immatics (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Mirjana Ziemer
Stock and Other Ownership Interests - Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Sanofi; Sun Pharma
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Sun Pharma
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Friedegund Elke Meier
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Lukas Flatz
Stock and Other Ownership Interests - Hookipa Pharma
Consulting or Advisory Role - Philogen
Research Funding - Hookipa Pharma; Mundipharma
Patents, Royalties, Other Intellectual Property - Hookipa Pharma
Travel, Accommodations, Expenses - Hookipa Pharma
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre
Consulting or Advisory Role - Pierre Fabre
Research Funding - BMS, Pfizer, Amgen, GSK, Roche, Novartis, Pierre Fabre, Replimune, MSD, Janssen, Kartos, IFX, Huyabio, Regeneron, IO Biotech, Philogen, Sotio, Kinnate, Astra Zenecca, Cytovation (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Mario Santinami
No Relationships to Disclose
 
Francesco Russano
No Relationships to Disclose
 
Imke von Wasielewski
No Relationships to Disclose
 
Thomas Eigentler
Stock and Other Ownership Interests - CureVac
Consulting or Advisory Role - Anaveon; Bristol-Myers Squibb; CureVac; Novartis; Pierre Fabre; Sanofi
Research Funding - CureVac (Inst); Genentech (Inst)
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
 
Iris Zalaudek
Honoraria - Fotofinder; MSD Oncology; Novartis; Philogen; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - Philogen; Sun Pharma
Travel, Accommodations, Expenses - Sun Pharma
 
Sebastian Haferkamp
Honoraria - Amgen; Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
 
Pietro Quaglino
Consulting or Advisory Role - Bristol Myers Squibb Foundation; MSD Oncology; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; Anaveon; AstraZeneca; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Erasca, Inc; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; MSD Oncology; Pfizer; Pierre Fabre; Replimune
 
Claus Garbe
Honoraria - CeCaVa; MSD Oncology; NeraCare GmbH; Philogen
Consulting or Advisory Role - CeCaVa; MSD Oncology; NeraCare GmbH; Philogen
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Katharina C. Kähler
Honoraria - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Philogen; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Philogen; Pierre Fabre
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche